JP2012500245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500245A5 JP2012500245A5 JP2011523405A JP2011523405A JP2012500245A5 JP 2012500245 A5 JP2012500245 A5 JP 2012500245A5 JP 2011523405 A JP2011523405 A JP 2011523405A JP 2011523405 A JP2011523405 A JP 2011523405A JP 2012500245 A5 JP2012500245 A5 JP 2012500245A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- hydromethanesulfonate
- hydromaleate
- hydrofumarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9001808P | 2008-08-19 | 2008-08-19 | |
| US61/090,018 | 2008-08-19 | ||
| PCT/EP2009/060592 WO2010020602A1 (en) | 2008-08-19 | 2009-08-17 | Dabigatran for percutaneous interventional cardiac catheterisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012500245A JP2012500245A (ja) | 2012-01-05 |
| JP2012500245A5 true JP2012500245A5 (enExample) | 2012-10-04 |
Family
ID=41258283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523405A Pending JP2012500245A (ja) | 2008-08-19 | 2009-08-17 | 経皮的インターベンション心臓カテーテル法のためのダビガトラン |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110301201A1 (enExample) |
| EP (1) | EP2328580A1 (enExample) |
| JP (1) | JP2012500245A (enExample) |
| KR (1) | KR20110044230A (enExample) |
| CN (1) | CN102123707A (enExample) |
| AR (1) | AR073077A1 (enExample) |
| AU (1) | AU2009284217A1 (enExample) |
| BR (1) | BRPI0917507A2 (enExample) |
| CA (1) | CA2734794A1 (enExample) |
| CL (1) | CL2011000361A1 (enExample) |
| CO (1) | CO6290686A2 (enExample) |
| EA (1) | EA201100358A1 (enExample) |
| EC (1) | ECSP11010825A (enExample) |
| IL (1) | IL210005A0 (enExample) |
| MA (1) | MA32563B1 (enExample) |
| MX (1) | MX2011001612A (enExample) |
| NZ (1) | NZ591108A (enExample) |
| TW (1) | TW201022235A (enExample) |
| WO (1) | WO2010020602A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102209544A (zh) | 2008-11-11 | 2011-10-05 | 贝林格尔.英格海姆国际有限公司 | 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良安全性的方法 |
| CA2791561A1 (en) * | 2010-03-01 | 2011-09-09 | Ratiopharm Gmbh | Dabigatran etexilate-containing oral pharmaceutical composition |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| CN102391250B (zh) * | 2011-08-29 | 2013-06-19 | 石药集团欧意药业有限公司 | 一种达比加群酯化合物、制备方法及其药物组合物 |
| CN102558153A (zh) * | 2012-02-08 | 2012-07-11 | 北京阜康仁生物制药科技有限公司 | 达比加群酯的新药用盐及其制备方法 |
| CN103420982B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 达比加群酯衍生物及其制备方法和用途 |
| CN103420994B (zh) * | 2012-05-24 | 2016-04-06 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420985B (zh) * | 2012-05-24 | 2015-09-23 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420984B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103524559B (zh) * | 2012-07-05 | 2016-09-28 | 西藏海思科药业集团股份有限公司 | 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途 |
| CN103539779B (zh) * | 2012-07-13 | 2016-12-21 | 四川海思科制药有限公司 | 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途 |
| US20150225370A1 (en) * | 2012-09-28 | 2015-08-13 | Ranbaxy Laboratories Limited | Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof |
| US9399616B2 (en) * | 2012-10-22 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
| WO2014145986A1 (en) | 2013-03-15 | 2014-09-18 | Verseon, Inc. | Multisubstituted aromatic compounds as serine protease inhibitors |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| KR20170048410A (ko) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
| AU2016224974B2 (en) | 2015-02-27 | 2019-09-26 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| IL280078B2 (en) | 2018-07-13 | 2024-04-01 | Verseon Int Corporation | Thrombin inhibitors, formulations, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1870100T1 (sl) * | 2002-03-07 | 2012-05-31 | Boehringer Ingelheim Int | Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline |
| CA2587026A1 (en) * | 2004-10-25 | 2006-05-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| AR061996A1 (es) * | 2006-07-17 | 2008-08-10 | Boehringer Ingelheim Int | Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular |
| JP2009543844A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 直接トロンビン阻害剤の新しい小児適応症 |
| EP2074112A1 (en) * | 2006-10-10 | 2009-07-01 | Boehringer Ingelheim International GmbH | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
-
2009
- 2009-08-17 EA EA201100358A patent/EA201100358A1/ru unknown
- 2009-08-17 EP EP09781886A patent/EP2328580A1/en not_active Withdrawn
- 2009-08-17 AU AU2009284217A patent/AU2009284217A1/en not_active Abandoned
- 2009-08-17 KR KR1020117003645A patent/KR20110044230A/ko not_active Withdrawn
- 2009-08-17 JP JP2011523405A patent/JP2012500245A/ja active Pending
- 2009-08-17 WO PCT/EP2009/060592 patent/WO2010020602A1/en not_active Ceased
- 2009-08-17 BR BRPI0917507A patent/BRPI0917507A2/pt not_active IP Right Cessation
- 2009-08-17 NZ NZ591108A patent/NZ591108A/xx not_active IP Right Cessation
- 2009-08-17 CN CN2009801318235A patent/CN102123707A/zh active Pending
- 2009-08-17 CA CA2734794A patent/CA2734794A1/en not_active Abandoned
- 2009-08-17 MX MX2011001612A patent/MX2011001612A/es not_active Application Discontinuation
- 2009-08-17 US US13/058,920 patent/US20110301201A1/en not_active Abandoned
- 2009-08-18 AR ARP090103168A patent/AR073077A1/es unknown
- 2009-08-18 TW TW098127736A patent/TW201022235A/zh unknown
-
2010
- 2010-12-15 IL IL210005A patent/IL210005A0/en unknown
-
2011
- 2011-02-11 EC EC2011010825A patent/ECSP11010825A/es unknown
- 2011-02-15 MA MA33616A patent/MA32563B1/fr unknown
- 2011-02-17 CO CO11018905A patent/CO6290686A2/es not_active Application Discontinuation
- 2011-02-18 CL CL2011000361A patent/CL2011000361A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9809545B2 (en) | Factor XIa inhibitors | |
| TWI359140B (enExample) | ||
| JP2007537187A5 (enExample) | ||
| CA2674436A1 (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| US9777002B2 (en) | Inhibitors of the renal outer medullary potassium channel | |
| TWI388345B (zh) | 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型 | |
| US10173998B2 (en) | Antifungal compound process | |
| JP2009514837A5 (enExample) | ||
| US20080200514A1 (en) | Indications for Direct Thrombin Inhibitors | |
| JP2010515715A5 (enExample) | ||
| KR101775304B1 (ko) | 퀴놀론 화합물의 제조 방법 | |
| JP2017528494A (ja) | ｓＧＣ刺激剤 | |
| JP2006523216A5 (enExample) | ||
| NZ592508A (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| US20190177298A1 (en) | Antifungal Compound Process | |
| US20150322056A1 (en) | Factor IXa Inhibitors | |
| JP2009510064A5 (enExample) | ||
| JP2010516700A5 (enExample) | ||
| JP2014532754A5 (enExample) | ||
| CA2657266A1 (en) | New indications for direct thrombin inhibitors in the cardiovascular field | |
| CN115315423A (zh) | 取代芳基类化合物 | |
| WO2008009210A8 (fr) | Composés de dihydropyrimidine optiquement purs et leurs utilisations dans la fabrication d'un médicament pour traiter ou prévenir des viroses | |
| EP2765860A1 (en) | Mineralocorticoid receptor antagonists | |
| US20250243228A1 (en) | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS | |
| JP2011500575A5 (enExample) |